Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Chair and Presenter Neal D. Shore, MD, FACS, Sia Daneshmand, MD, and Guru P. Sonpavde, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA activity titled “Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40qGkJH. CME/MOC/AAPA credit will be available until December 28, 2024.
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and Richard S. Finn, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?" For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2okTvdb. CME credit will be available until March 7, 2019.
Chair, Anthony R. Mato, MD, MSCE, Kristen Battiato, MSN, RN, AGNP-C, Dipti Gupta, MD, MPH, and Amber C. King, PharmD, BCOP, prepared useful Practice Aids pertaining to B-cell cancers for this CME/MOC/NCPD activity titled “Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at http://bit.ly/3cHX3zm. CME/MOC/NCPD credit will be available until October 3, 2023.
Chair and Presenters Matthew D. Galsky, MD, Shilpa Gupta, MD, and Andrea Necchi, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA/IPCE activity titled “Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3QlbwW0. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
Mgh COVID-19 Treatment Guidance March 17, 2020Ken Yale
This document was developed by members of the ID division at MGH in conjunction with pharmacy, radiology, and other medicine divisions to provide guidance to frontline clinicians caring for patients with COVID-19. This document covers potential off-label and/or experimental use of medications and immunosuppression management for transplant patients as well as a suggested laboratory work up. It does NOT cover recommendations for infection control, PPE, management of hypoxemia or other complications in patients with COVID-19. This is a living document that will be updated in real time as more data emerge.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Chair and Presenter Neal D. Shore, MD, FACS, Sia Daneshmand, MD, and Guru P. Sonpavde, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA activity titled “Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40qGkJH. CME/MOC/AAPA credit will be available until December 28, 2024.
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and Richard S. Finn, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?" For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2okTvdb. CME credit will be available until March 7, 2019.
Chair, Anthony R. Mato, MD, MSCE, Kristen Battiato, MSN, RN, AGNP-C, Dipti Gupta, MD, MPH, and Amber C. King, PharmD, BCOP, prepared useful Practice Aids pertaining to B-cell cancers for this CME/MOC/NCPD activity titled “Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at http://bit.ly/3cHX3zm. CME/MOC/NCPD credit will be available until October 3, 2023.
Chair and Presenters Matthew D. Galsky, MD, Shilpa Gupta, MD, and Andrea Necchi, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA/IPCE activity titled “Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3QlbwW0. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
Mgh COVID-19 Treatment Guidance March 17, 2020Ken Yale
This document was developed by members of the ID division at MGH in conjunction with pharmacy, radiology, and other medicine divisions to provide guidance to frontline clinicians caring for patients with COVID-19. This document covers potential off-label and/or experimental use of medications and immunosuppression management for transplant patients as well as a suggested laboratory work up. It does NOT cover recommendations for infection control, PPE, management of hypoxemia or other complications in patients with COVID-19. This is a living document that will be updated in real time as more data emerge.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Arjun Balar, MD, and Petros Grivas, MD, PhD, prepared useful practice aids pertaining to bladder cancer management for this CME activity titled "Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2GpacAq. CME credit will be available until December 30, 2019.
Chair, Jamie E. Chaft, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/NCPD activity titled “Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC.” For the full presentation, downloadable Practice Aids and complete CME/MOC/CC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3fcc3qs. CME/MOC/CC/NCPD credit will be available until July 11, 2022.
Linda R. Duska, MD, MPH, prepared useful practice aids pertaining to endometrial and cervical cancers for this CME/MOC activity titled Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers. For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2Uk5F72. CME/MOC credit will be available until June 17, 2021.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Chair, Taofeek K. Owonikoko, MD, PhD, Carl M. Gay, MD, PhD, and Ticiana Leal, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/NCPD/AAPA activity titled “Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3pijZiM. CME/MOC/NCPD/AAPA credit will be available until July 4, 2024.
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Chair & Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Tiffany A. Richards, PhD, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to multiple myeloma for this NCPD/ILNA activity titled “Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA information, and to apply for credit, please visit us at https://bit.ly/3ZSymre. NCPD/ILNA credit will be available until May 27, 2024.
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Carei3 Health
i3 Health is pleased to make this slide deck from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program)
Medical Oncologist, Center for Head & Neck Oncology
Dana-Farber Cancer Institute, and Deborah Wong, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, UCLA Medical Center, was presented at a live educational event at the 2024 Multidisciplinary Head and Neck Cancers Symposium. It will provide expert perspectives on harnessing immunotherapy in recurrent/metastatic HNSCC to provide comprehensive care.
Ronan J. Kelly, MD, MBA; Russell Hales, MD; and Yelena Y. Janjigian, MD, discuss esophageal and GEJ cancer in this CME activity titled "Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy." For the full presentation, downloadable Practice Aids, complete CME information, and to apply for credit, please visit us at https://bit.ly/3brUnVM. CME credit will be available until November 10, 2021.
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
Обзор последних рекомендаций DHHS , индивидуализация лечения в отдельных группах пациентов, минимизация побочных эффектов и межлекарственных взаимодействий
Johanna C. Bendell, MD, George P. Kim, MD, and Eileen M. O'Reilly, MD, prepared useful practice aids pertaining to pancreatic cancer management for this CME activity titled "Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2K1bR0N. CME credit will be available until July 4, 2019.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
More Related Content
Similar to Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Arjun Balar, MD, and Petros Grivas, MD, PhD, prepared useful practice aids pertaining to bladder cancer management for this CME activity titled "Keeping Pace With Immunotherapy Advances in Bladder Cancer: Tools for Winning the Race and Optimizing Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2GpacAq. CME credit will be available until December 30, 2019.
Chair, Jamie E. Chaft, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/NCPD activity titled “Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC.” For the full presentation, downloadable Practice Aids and complete CME/MOC/CC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3fcc3qs. CME/MOC/CC/NCPD credit will be available until July 11, 2022.
Linda R. Duska, MD, MPH, prepared useful practice aids pertaining to endometrial and cervical cancers for this CME/MOC activity titled Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers. For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2Uk5F72. CME/MOC credit will be available until June 17, 2021.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Chair, Taofeek K. Owonikoko, MD, PhD, Carl M. Gay, MD, PhD, and Ticiana Leal, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/NCPD/AAPA activity titled “Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3pijZiM. CME/MOC/NCPD/AAPA credit will be available until July 4, 2024.
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Chair & Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Tiffany A. Richards, PhD, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to multiple myeloma for this NCPD/ILNA activity titled “Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA information, and to apply for credit, please visit us at https://bit.ly/3ZSymre. NCPD/ILNA credit will be available until May 27, 2024.
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Carei3 Health
i3 Health is pleased to make this slide deck from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program)
Medical Oncologist, Center for Head & Neck Oncology
Dana-Farber Cancer Institute, and Deborah Wong, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, UCLA Medical Center, was presented at a live educational event at the 2024 Multidisciplinary Head and Neck Cancers Symposium. It will provide expert perspectives on harnessing immunotherapy in recurrent/metastatic HNSCC to provide comprehensive care.
Ronan J. Kelly, MD, MBA; Russell Hales, MD; and Yelena Y. Janjigian, MD, discuss esophageal and GEJ cancer in this CME activity titled "Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy." For the full presentation, downloadable Practice Aids, complete CME information, and to apply for credit, please visit us at https://bit.ly/3brUnVM. CME credit will be available until November 10, 2021.
Key Slides on Individualizing ART Management Based on Treatment Safety and To...hivlifeinfo
Обзор последних рекомендаций DHHS , индивидуализация лечения в отдельных группах пациентов, минимизация побочных эффектов и межлекарственных взаимодействий
Johanna C. Bendell, MD, George P. Kim, MD, and Eileen M. O'Reilly, MD, prepared useful practice aids pertaining to pancreatic cancer management for this CME activity titled "Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2K1bR0N. CME credit will be available until July 4, 2019.
Similar to Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies (20)
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
More from PVI, PeerView Institute for Medical Education (20)
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies
1. A Snapshot of Approved Therapies and
Ongoing Investigations in Urothelial Carcinoma
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
DRUG/TARGET INDICATION DOSING
Approved for the treatment of adult pts with locally advanced UC or mUC who have previously
received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy in the
neoadjuvant/adjuvant, locally advanced, or metastatic setting
Approved for the treatment of pts with locally advanced UC or mUC who are ineligible for
cisplatin-containing chemotherapy and have received ≥1 prior line of therapy
Antibody–Drug Conjugates
Enfortumab vedotin6
Nectin-4
1.25 mg/kg (≤125 mg)
as IV infusion over
30 min on d 1, 8, and 15 of
a 28-d cycle until disease
progression or toxicity
Approved for the treatment of pts with locally advanced or metastatic disease
who are platinum ineligible
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative
platinum-containing chemotherapy tx
Approved for the treatment of pts with BCG-unresponsive, high-risk NMIBC with CIS with
or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Pembrolizumab4
PD-1
200 mg every 3 wk
or 400 mg every 6 wk
240 mg every 2 wk
or 480 mg every 4 wk
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative cisplatin tx
Approved for the adjuvant treatment of pts with UC who are at high risk of
recurrence after undergoing radical resection of UC
Nivolumab3
PD-1
Immune Checkpoint Inhibitors
Atezolizumab1
PD-L1
840 mg every 2 wk,
1,200 mg every 3 wk,
or 1,680 mg every 4 wk
Approved for the treatment of newly diagnosed pts with cisplatin-ineligible locally
advanced UC or mUC and PD-L1+ tumors (tumor-infiltrating ICs covering ≥5%
of the tumor area) or who are platinum ineligible
Companion diagnostic: Ventana PD-L1 (SP142) Assay
Approved for the treatment of pretreated pts with locally advanced UC or mUC who
progressed on prior platinum-based tx or relapsed within 1 y of perioperative
platinum-containing chemotherapy tx
Approved for maintenance treatment of pts with locally advanced UC
or mUC that has not progressed with first-line platinum-containing chemotherapy
Avelumab2
PD-L1
800 mg every 2 wk
Trop-2
10 mg/kg on d 1 and 8,
every 21 d until disease
progression or toxicity
Approved for the treatment of pts with locally advanced
UC or mUC who have had prior treatment with a PD-1 or PD-L1 inhibitor
and a platinum-containing chemotherapy regimen
Sacituzumab govitecan7
Approved for the treatment of pretreated pts with locally advanced UC or mUC who have
FGFR2 or FGFR3 genetic alterations and who progressed on prior platinum-based tx
or relapsed within 1 y of perioperative platinum-containing chemotherapy tx
Companion diagnostic: therascreen®
FGFR RGQ RT-PCR Kit
Erdafitinib5
FGFR
8 mg daily with
an increase
to 9 mg daily based on
PO4
levels and tolerability
at 14 to 21 d
FGFR Inhibitors
Therapeutic Targets, Indications, and Dosing Information
2. 1. Tecentriq (atezolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf. 2. Bavencio (avelumab) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s005lbl.pdf. 3. Opdivo (nivolumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125554s097lbledt.pdf.
4. Keytruda (pembrolizumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s113lbl.pdf. 5. Balversa (erdafitinib) Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 6. Padcev (enfortumab vedotin-ejfv) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf.
7. Trodelvy (sacituzumab govitecan-hziy) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf. 8. www.clinicaltrials.gov.
Selected Ongoing Clinical Trials of Innovative Treatment
Options in Urothelial Carcinoma8
First-Line Metastatic Second-Line Metastatic
Bladder Preservation
Adjuvant MIBC
CheckMate -901 (NCT03036098) phase 3:
nivolumab + ipilimumab vs nivolumab
+ chemo vs chemo
NILE (NCT03682068) phase 3:
durvalumab + chemo ± tremelimumab
NCT04863885 phase 1/2:
ipilimumab + nivolumab combined with
sacituzumab govitecan for cisplatin-ineligible pts
vs chemo
NORSE (NCT03473743) phase 2:
erdafitinib + cetrelimab vs erdafitinib
THOR (NCT03390504) phase 3:
erdafitinib vs chemo vs pembrolizumab in pts
with selected FGFR mutations
TROPHY-U-01 (NCT03547973) phase 2:
sacituzumab govitecan
TROPiCS-04 (NCT04527991) phase 3:
sacituzumab govitecan vs chemo
NMIBC
Neoadjuvant
SunRISe-2 (NCT04658862) phase 3:
TAR-200 + cetrelimab vs gemcitabine/cisplatin
or RT
S1806 (NCT03775265) phase 3:
atezolizumab ± CRT in localized MIBC
AMBASSADOR (NCT03244384) phase 3:
pembrolizumab vs observation
IMvigor010 (NCT02450331) phase 3:
atezolizumab vs observation
ALBAN (NCT03799835) phase 3:
atezolizumab + BCG vs BCG
KEYNOTE-676 (NCT03711032) phase 3:
SunRISe-1 (NCT04640623) phase 2b:
TAR-200 + cetrelimab vs TAR-200 vs cetrelimab
pembrolizumab + BCG vs BCG
SWOG 1605 (NCT02844816) phase 2:
atezolizumab monotherapy
ENERGIZE (NCT03661320) phase 3:
nivolumab + chemo or nivolumab +
linrodostat (IDO1 inhibitor) + chemotherapy
→ immuno-oncology therapy after radical
cystectomy vs chemotherapy
KEYNOTE-866 (NCT03924856) phase 3:
Perioperative pembrolizumab +
neoadjuvant chemo vs perioperative placebo +
neoadjuvant chemo
NCT04209114 phase 3:
neoadjuvant and adjuvant nivolumab +
bempegaldesleukin vs nivolumab alone vs
SOC in pts with MIBC who are cisplatin ineligible
KEYNOTE-B15 (NCT04700124) phase 3:
pembrolizumab + enfortumab vedotin
NCT04241185 phase 3:
pembrolizumab + CRT in MIBC
A Snapshot of Approved Therapies and
Ongoing Investigations in Urothelial Carcinoma
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
3. Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
• In general, checkpoint inhibitor therapy should be continued with close monitoring,
with the exception of some neurologic, hematologic, and cardiac toxicities
Minimal or no symptoms; diagnostic changes only
Grade 1
• Hold checkpoint inhibitor therapy for most grade 2 toxicities
• Consider resuming immunotherapy when symptoms and/or laboratory values
revert to grade 1 or lower
• Corticosteroids (initial dose of 0.5-1 mg/kg/d of prednisone or equivalent) may
be administered
Grade 3 toxicities
• Hold checkpoint inhibitor therapy
• Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/d or methylprednisolone
IV 1-2 mg/kg/d)
• If symptoms do not improve with 48-72 hours of high-dose corticosteroids,
infliximab may be offered for some toxicities
• Taper corticosteroids over the course of at least 4-6 weeks
• When symptoms and/or laboratory values revert to grade 1 or lower, rechallenging
with immunotherapy may be offered; however, caution is advised, especially in
those patients with early-onset irAEs; dose adjustments are not recommended
Grade 4 toxicities
• In general, permanent discontinuation of checkpoint inhibitor therapy is warranted,
with the exception of endocrinopathies that have been controlled by hormone
replacement
Grade 2
Mild to moderate symptoms
Severe or life-threatening symptoms
Grades 3/4
Immune checkpoint inhibitors are associated with important clinical
benefits, but general immunologic enhancement can also lead to a
unique spectrum of immune-related adverse events (irAEs)1,2
irAEs are often diagnosed by
exclusion; other causes should
be ruled out (including AEs of
other therapies used), but
immunotherapy-related toxicity
should always be included
in the differential
There should be a high level of
suspicion that new symptoms
are treatment related; early
recognition, evaluation, and
treatment of irAEs plus patient
education are essential for
best outcomes
Depending on the severity
of irAEs, management may
require corticosteroid or
other immunosuppressive
treatment as well as
interruption or
discontinuation of therapy
If appropriate,
immunosuppressive
treatment is used; patients
generally recover from irAEs
How should irAEs be diagnosed?
What are the general recommendations
for irAE management?
What is the spectrum of potential irAEs?
Pancreatitis,
autoimmune diabetes
Colitis
Enteritis
Encephalitis, aseptic meningitis
Thyroiditis, hypothyroidism,
hyperthyroidism
Dry mouth, mucositis
Hypophysitis
Uveitis
Pneumonitis
Thrombocytopenia,
anemia
Hepatitis
Adrenal insufficiency
Nephritis
Vasculitis
Arthralgia
Neuropathy
Rash, vitiligo
Myocarditis
Any organ system can be affected; commonly occurring irAEs are pulmonary
(pneumonitis), dermatologic (rash, pruritus, blisters, ulcers, vitiligo),
gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis),
and endocrine (thyroiditis, hypophysitis, adrenal insufficiency)
Why do
irAEs occur?
“Taking the brakes off”
of the immune system can
help the body fight cancer,
but it can also lead to
toxicity from a
“supercharged”
immune system.
4. Safety Management for
FGFR Inhibitor Therapy8,9
Erdafitinib
Mucositis, other oral toxicities
Oral
Monitor for toxicities
Refer to dermatology and
podiatry as needed
Skin and Nail
Dietary phosphate may require
restriction
Individualized dietary plan
from nutrition professional
Consider adding a
non–calcium-containing
phosphate binder (eg,
sevelamer carbonate)
Dietary
FGF FGF
FGF
FGF
FGFR
HSPG
FGF FGF
FGFRL1
SEF
SPRY
FRS2
PLC-y
DAG STAT
GAB1
SOS
GRB2
RAS RAF
MEK
ERK MKP3
MKP1
AKT
PKC
PI3K
Nucleus
Transcription of
target genes
Cytoplasm
Extracellular
PIP2
P
P
P
P
P
P
P
P
P
P
P
P
IP3
Plasma membrane
Proliferation
and survival
Resistance to
anticancer agents
Neoangiogenesis
FGFR alterations:
Amplification (receptor
overexpression) or
mutation/translocation
(ligand-independent
signaling)
FGF ligand:
Amplification
(autocrine) or
ECM/stromal-
cell release
(paracrine)
FGFR in UC3,4
FGFR Signaling Pathway7
FGFR is altered in 15% to 20% of advanced UC.5
Mutated FGFR3 is present in 37% of upper-tract UC.6
FGFRs are a family of receptor tyrosine kinases that are upregulated in multiple different cancers
and are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell
survival; alterations in the FGFR gene, such as mutations and translocations, have been implicated
in the pathogenesis of UC
Eye exams
Withhold for any occurrence of
CSR or RPED
Discontinue permanently if CSR/
RPED symptoms do not resolve
in 4 wk or if they escalate to grade 4
Ocular
Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40
5. Sacituzumab Govitecan
Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) are molecules composed of an antibody chosen based on its ability to target a
tumor-specific protein linked to a cytotoxic payload or drug, enabling it to deliver a cytotoxic agent directly to the
targeted cells while minimizing toxicity to healthy cells10
Enfortumab Vedotin
Peripheral Neuropathy
Generally resolves/remains at grade 1
Hyperglycemia
Monitor blood glucose (patients with/at risk for
diabetes or hyperglycemia)
Maculopapular Diffuse Rash
Topical steroids
Antihistamines
Dose reductions/delays
Systemic corticosteroids (special cases)
Diarrhea
Educate patients
Hydration with electrolytes
Anti-diarrheal medications
Best supportive care
Safety Management for Antibody–Drug
Conjugate Therapy11-13
1Binds to
antigen
2Complex is internalized
and traffics to lysosome
3Payload is released
and causes cell death
Neutropenia
Consider growth factor support
Dose reduction or hold
Sacituzumab Govitecan
Enfortumab Vedotin
Target: Nectin-4, a type 1 transmembrane cell
adhesion molecule overexpressed in epithelial cancers
Linker: Protease cleavable
Payload: MMAE
Target: Trop-2, an epithelial cell-surface glycoprotein
highly expressed in muscle-invasive disease
Linker: Hydrolysable
Payload: SN-38, the active metabolite of irinotecan
1. Postow MA et al. N Engl J Med. 2018;378:158-168. 2. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1768. 3. https://tcga-data.nci.nih.gov/docs/publications/tcga.
4. Knowles MA et al. Nat Rev Cancer. 2015;15:25-41. 5. Rodriguez-Vida A et al. J Hematol Oncol. 2015;8:119. 6. Li Q et al. Curr Urol Rep. 2016;17:12. 7. Touat M et al. Clin Cancer Res. 2015;21:2684-2694.
8. Loriot Y et al. N Engl J Med. 2019;381:338-348. 9. Balversa (erdafitinib) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212018s001lbl.pdf. 10. Parslow AC et al.
Biomedicines. 2016;4:14. 11. Rosenberg JE et al. J Clin Oncol. 2019;37:2592-2600. 12. Loriot Y et al. Ann Oncol. 2020;31(suppl 4)s1142-s1215. 13. Petrylak DP et al. J Clin Oncol. 2020;38(suppl): Abstract 5027.
Guide to Managing Adverse Events Associated
With Therapies for Urothelial Carcinoma
Therapeutic Targets, Current Status/Indication, and Dosing Information
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/RPD40